Recent Advances of Dendritic Cells (DCs)-Based Immunotherapy for Malignant Gliomas
| Autor: | Der-Yang Cho, Shinn-Zong Lin, Wen-Kuang Yang M.D., PhD., Den-Mei Hsu, Han-Chung Lee, Wen-Yeun Lee, Shih-Ping Liu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: | |
| Zdroj: | Cell Transplantation, Vol 18 (2009) |
| Druh dokumentu: | article |
| ISSN: | 0963-6897 1555-3892 |
| DOI: | 10.3727/096368909X12483162196962 |
| Popis: | Immunotherapy is a new light of hope for the treatment of malignant gliomas. The brain is no longer believed to be an immunologically privileged organ. The major advantage of immunotherapy is the tumor-specific cytotoxic effect on the tumor cells with minimal side effects. Autologous dendritic cells (DCs)-based immunotherapy is a promising and feasible method. DCs are the most potent antigen-presenting cells (APCs). DCs prime T lymphocytes by epitopic major histocompatibility (MHC) class I and II for CD8 + cytotoxic T lymphocytes (CTLs) and CD4 + T helper cells, respectively. From the tissue specimen examination after DCs-based immunotherapy, CD8 + CTLs have replaced T regulatory cells (Tregs) as the major dominant tissue infiltrating lymphocytes (TILs). CD8 + CTLs play a key role in the tumor response, which may also be effective against cancer stem cells. DCs themselves also produce many cytokines including interferon-γ and interleukin (IL-2) to kill the tumor cells. From the preliminary better outcomes in the literature for malignant gliomas, DC-based immunotherapy may improve tumor response by increasing the survival rate and time. It is recommended that DC-based immunotherapy is applied as soon as possible with conjunctive radiotherapy and chemotherapy. Malignant gliomas have heterogeneity of tissue-associated antigens (TAAs). To find universal common antigens through different kinds of tumor culture may be the essential issue for tumor vaccine development in the future. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|